other material
confidence high
sentiment positive
materiality 0.55
MIRA Pharma reports no brain toxicity in FDA-required Ketamir-2 study
MIRA PHARMACEUTICALS, INC.
- Ketamir-2 showed no mortality, adverse signs, or brain lesions in rats at high doses.
- Positive control MK-801 caused vacuolation and neuronal necrosis (Olney lesions).
- Results to be submitted to FDA as part of ongoing regulatory communications.
- Study supports Ketamir-2's safety profile versus ketamine-linked neurotoxicity.